Recent Updates
Recently added Catalysts

PLX-200

Phase 3

Juvenile Neuronal Ceroid Lipofuscinosis | Small molecule | Rare Disease |Polaryx Therapeutics, Inc. Common Stock|Last Updated: May 29, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment39
FDA Designations
FAST_TRACK
Clinical trial landscape

PLX-200 · 1 trial · 1 indication

Phase 3 1
NCT04637282Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3Juvenile Neuronal Ceroid Lipofuscinosis
NOT YET_RECRUITING39 Analytics
PHASE3NOT YET_RECRUITING
Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3
Juvenile Neuronal Ceroid Lipofuscinosis
NCT0463728239
Unlock trial analytics
Study Design & Arms
Interventions
NameTypeDescription
PLX-200DRUG15 mg/mL oral solution of experimental drug
PlaceboDRUGTaste and color-matched drug-free solution
Unlock Study Design Details
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT04637282studyFirstPostDate: changed